AstraZeneca has sold rights to its Zomig migraine drug to Grunenthal in a deal worth up to $302 million. The deal is part of AZ's ongoing tactic of selling off rights to older products to plump up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback